

**Cell Reports, Volume 30**











**Supplemental Information**

**Mitochondrial Oxidative Phosphorylation**

**Regulates the Fate Decision between Pathogenic**

**Th17 and Regulatory T Cells**


**Boyoung Shin, Gloria A. Benavides, Jianlin Geng, Sergei B. Koralov, Hui Hu, Victor M. Darley-Usmar, and Laurie E. Harrington**




**Supplementary Figure 1. Related to Figures 1 and 2. OXPHOS inhibition alters metabolic profiles of CD4 T cells during Th17 differentiation.**

(A-E) The OCR and ECAR of CD4 T cells under Th17 differentiation conditions were measured at indicated time points. (A) Basal ECAR of CD4 T cells. (B-D) The OCR of CD4 T cells during Th17 development in the presence of vehicle or oligomycin were measured at (B) 24h, (C) 48h and (D) 72h. (E) The basal ECAR of CD4 T cells at 24h of Th17 culture with vehicle or oligomycin treatment (4-7 independent experiments). (F) The percent of live cells were determined by flow cytometry using live/dead exclusion dye after Th17 differentiation in the presence of vehicle or oligomycin for 3 days (18 independent experiments). (G,H) 2D2 CD4 T cells were differentiated under Th17 conditions in the presence of vehicle or oligomycin. After 5 days, cells were transferred into Rag1 deficient recipient mice. Proliferation of cells from cervical lymph nodes was analyzed using flow cytometry on day 16-19 (3 independent experiments, n=13-15). Graphs show the average  $\pm$  S.D.; (A,E,G,H) One-way ANOVA, (F) unpaired t-test, \* $p < 0.05$ , \*\*\* $p < 0.001$ .


**A. Pathogenic Th17 (IL-1 $\beta$ +IL-6+IL-23)**




**Nonpathogenic Th17 (IL-1 $\beta$ +IL-6)**



**B. GSE14308 Th17 vs. Treg (DN)**




**C. WT Th17 up ( vs. *Batf*<sup>-/-</sup> Th17)**




**Supplementary Figure 2. Related to Figures 2 and 3. Mitochondrial OXPHOS is necessary for expression of both pathogenic and BATF-dependent Th17 gene signatures.**

GSEA plots demonstrate enrichment of RNA sequencing data sets from vehicle treated and oligomycin treated CD4 T cells with previously published data sets. **(A)** Enrichment with pathogenic vs. non-pathogenic Th17 gene signature. **(B)** Enrichment with Th17 vs. Treg signature. **(C)** Enrichment with WT vs. BATF deficient Th17 gene set. NES=Normalized Enrichment Score, FDR= False Detection Rate.


A.



B.




C.



**Supplementary Figure 3. Related to Figure 2. Mitochondrial OXPHOS regulates the balance between Th17 and Treg.**





Naïve CD4 T cells were activated under Th17 conditions for 72h in the presence of vehicle or indicated OXPHOS inhibitor. **(A)** The relative expression of indicated genes were measured by realtime PCR (3 independent experiments). **(B,C)** The frequency of IL-17A<sup>+</sup> and Foxp3<sup>+</sup> CD4 T cells was assessed by flow cytometry (10 independent experiments for vehicle and oligomycin, 3 independent experiments for antimycin + rotenone). Graphs show the average  $\pm$  S.D.; **(A)** Ratio paired t-test, **(C)** One-way ANOVA \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .





**Supplementary Figure 4. Related to Figure 2. Mitochondrial OXPHOS skews STAT5/STAT3 signaling.**

**(A)** Naïve CD4 T cells were cultured under Th17 conditions in the presence of vehicle or oligomycin for 60h. Phosphorylation of STAT5 was measured by flow cytometry (2-3 independent experiments). **(B)** GSEA plots demonstrate enrichment of RNA sequencing data sets from vehicle treated and oligomycin treated CD4 T cells with previously published STAT5A target gene set. **(C)** Naïve CD4 T cells were cultured under Th17 conditions in the presence of vehicle or oligomycin for 24h. Phosphorylation of STAT3 was measured by flow cytometry (2-3 independent experiments). **(D)** Naïve CD4 T cells from WT or STAT3C<sup>+/+</sup> mice were activated under Th17 conditions in the presence of vehicle or oligomycin for 72h. Representative plots are gated on live CD4 T cells and show the frequency of IL-17A<sup>+</sup> and Foxp3<sup>+</sup> (3 independent experiments). Graphs show the average  $\pm$  S.D.; (A,C) unpaired t-test and (D) One-way ANOVA \*p<0.05, \*\*p<0.01.



**Supplementary Figure 5. Related to Figures 3, 4, and 5. TCR signal strength regulates BATF and mTOR activation but BATF overexpression does not suppress Foxp3<sup>+</sup> Treg generation in oligomycin treated Th17 cultures.**

(A) Activated CD4 T cells were retrovirally transduced with EGFR-empty vector (EV) or EGFR-BATF overexpression vector (OE) at 24h. The expression of Foxp3<sup>+</sup> and IL-17A<sup>+</sup> CD4 T cells (gated on hNGFR<sup>+</sup>) were analyzed on day 3-4 using flow cytometry (4 independent experiments). (B,C) Naïve CD4 T cells were activated with varying concentrations of plate-bound anti-CD3 $\epsilon$  and 1 $\mu$ g/ml of anti-CD28 under Th17 conditions for 24h. Expression of BATF and phosphorylation of S6 (pS6) or 4E-BP1 (p4E-BP1) were measured by flow cytometry (3-4 independent experiments). Graphs show the average  $\pm$  S.D.; One-way ANOVA ns=not significant, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.